Disruption of the 12/15-lipoxygenase gene diminishes atherosclerosis in apo E-deficient mice

Journal of Clinical Investigation

Volumn 103, Issue 11, 1999, Pages 1597-1604

  Cyrus, Tillmann ^a   Witztum, Joseph L ^b   Rader, Daniel J ^a   Tangirala, Rajendra ^a   Fazio, Sergio ^c   Linton, MacRae F ^c   Funk, Colin D ^a  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF CALIFORNIA SAN DIEGO   (United States)

^c VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E; IMMUNOGLOBULIN G ANTIBODY; LIPOXYGENASE; LOW DENSITY LIPOPROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ARTICLE; ATHEROGENESIS; ATHEROSCLEROSIS; CONTROLLED STUDY; ENZYME INHIBITION; FOAM CELL; GENE DISRUPTION; HYPERLIPOPROTEINEMIA TYPE 3; LIPID OXIDATION; LIPID STORAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

EID: 0032752579     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI5897     Document Type: Article

References (61)

1. Peters, K.D., Kochaneck, K.D., and Murphy, S.L. 1998. Deaths: final data for 1996. Natl. Vital Stat. Rep. 47:2-6.
2. Steinberg, D., Parthasarathy, S., Carew, T.E., Khoo, J.C., and Witztum, J.L. 1989. Beyond cholesterol. Modifications of low-density lipoprotein that increase its atherogenicity. N. Engl. J. Med. 320:915-924.
3. Steinberg, D. 1997. Low density lipoprotein oxidation and its pathobiological significance. J. Biol. Chem. 272:20963-20966.
4. Berliner, J.A., and Heinecke, J.W. 1996. The role of oxidized lipoproteins in atherogenesis. Free Radic. Biol. Med. 20:707-727.
5. Henriksen, T., Mahoney, E.M., and Steinberg, D. 1981. Enhanced macrophage degradation of low density lipoprotein previously incubated with cultured endothelial cells: recognition by receptors for acetylated low density lipoproteins. Proc. Natl. Acad. Sci. USA. 78:6499-6503.
6. Steinbrecher, U.P., Parthasarathy, S., Leake, D.S., Witztum, J.L., and Steinberg, D. 1984. Modification of low density lipoprotein by endothelial cells involves lipid peroxidation and degradation of low density lipoprotein phospholipids. Proc. Natl. Acad. Sci. USA. 81:3883-3887.
7. Morel, D.W., DiCorletto, P.E., and Chisolm, G.M. 1984. Endochelial and smooth muscle cells alter low density lipoprotein in vitro by free radical oxidation. Arteriosclerosis. 4:357-364.
8. Heinecke, J.W., Rosen, H., and Chait, A. 1984. Iron and copper promote modification of low density lipoprotein by human arterial smooth muscle cells in culture. J. Clin. Invest. 74:1890-1894.
9. Parthasarathy, S., Printz, D.J., Boyd, D., Joy, L., and Steinberg, D. 1986. Macrophage oxidation of low density lipoprotein generates a modified form recognized by the scavenger receptor. Atherosclerosis. 6:505-510.
10. Ylä-Herttuala, S., et al. 1989. Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J. Clin. Invest. 84:1086-1095.
11. Palinski, W., et al. 1989. Low density lipoprotein undergoes oxidative modification in vivo. Proc. Natl. Acad. Sci. USA. 86:1372-1376.
12. Suarna, C., Dean, R.T., May, J., and Stocker, R. 1995. Human atherosclerotic plaque contains both oxidized lipids and relatively large amounts of alpha-tocopherol and ascorbate. Arterioscler. Thromb. Vasc. Biol. 15:1616-1624.
13. Palinski, W., et al. 1994. ApoE deficient mice are a model of lipoprotein oxidation in atherogenesis. Arterioscler. Thromb. 14:605-616.
14. Hörkkö, S., Miller, E., Branch, D.W., Palinski, W., and Witztum, J.L. 1997. The epitopes for some antiphospholipid antibodies are adducts of oxidized phospholipid and beta2 glycoprotein 1. Proc. Natl. Acad. Sci. USA. 94:10356-10361.
15. 2α-I: an index of lipid peroxidation in humans. Proc. Natl. Acad. Sci. USA. 95:3449-3454.
16. Praticó, D., et al. 1997. Localization of distinct F2-isoprostanes in human atherosclerotic lesions. J. Clin. Invest. 100:2028-2034.
17. Praticó, D., Tangirala, R.K., Rader, D.J., Rokach, J., and FitzGerald, G.A. 1998. Vitamin E suppresses isoprostane generation in vivo and reduces atherosclerosis in ApoE-deficient mice. Nat. Med. 10:1189-1192.
18. Witztum, J.L. 1994. The oxidation hypothesis of atherosclerosis. Lancet. 344:793-795.
19. Navab, M., et al. 1996. The Yin and Yang of oxidation in the development of the fatty streak. Arterioscler. Thromb. Vasc. Biol. 16:831-842.
20. Quinn, M.T., Parthasarathy, S., Fong, L.G., and Steinberg, D. 1987. Oxidatively modified low density lipoproteins: a potential role in recruitment and retention of monocyte/macrophages during atherogenesis. Proc. Natl. Acad. Sci. USA. 84:2995-2998.
21. Cushing, S.D., et al. 1990. Minimally modified low density lipoprotein induces monocyte chemotactic protein 1 in human endothelial cells and smooth muscle cells. Proc. Natl. Acad. Sci. USA. 87:5134-5138.
22. Watson, A.D., et al. 1997. Structural identification by mass spectrometry of oxidized phospholipids in minimally oxidized low density lipoprotein that induce monocyte/endothelial interactions and evidence for their presence in two. J. Biol. Chem. 272:13597-13607.
23. Folcik, V.A., Aamir, R., and Cathcart, M.K. 1997. Cytokine modulation of LDL oxidation by activated human monocytes. Arterioscler. Thromb. Vasc. Biol. 17:1954-1961.
24. Nagy, L., Tontonoz, P., Alvarez, J.G., Chen, H., and Evans, R.M. 1998. Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell. 93:229-240.
25. Parthasarathy, S., Wieland, E., and Steinberg, D. 1989. A role for endothelial cell lipoxygenase in the oxidative modification of low density lipoprotein. Proc. Natl. Acad. Sci. USA. 86:1046-1050.
26. Kühn, H., Belkner, J., Suzuki, H., and Yamamoto, S. 1994. Oxidative modification of human lipoprotein by lipoxygenases of different positional specificities. J. Lipid Res. 35:1749-1759.
27. Yamamoto, S. 1992. Mammalian lipoxygenases: molecular structures and functions. Biochim. Biophys. Acta. 1128:117-131.
28. Funk, CD. 1996. The molecular biology of mammalian lipoxygenases and the quest for eicosanoid functions using lipoxygenase-deficient mice. Biochim. Biophys. Acta. 1304:65-84.
29. Belkner, J., Stender, H., and Kühn, H. 1998. The rabbit 15-lipoxygenase preferentially oxygenates LDL cholescerol esters, and this reaction does not require vitamin E. J. Biol. Chem. 273:23225-23232.
30. Takahashi, Y., et al. 1993. Investigation of the oxygenation of phospholipids by the porcine leukocyte and human platelet arachidonate 12-lipoxygenases. Eur. J. Biochem. 218:165-171.
31. Sloane, D.L., Leung, R., Craik, C.S., and Sigal, E. 1991. A primary determinant for lipoxygenase positional specificity. Nature. 354:149-152.
32. Chen, X.S., Kurre, U., Jenkins, N.A., Copeland, N.G., and Funk, C.D. 1994. cDNA cloning, expression, mutagenesis of C-terminal isoleucine, genomic structure, and chromosomal localizations of murine 12-lipoxygenases. J. Biol. Chem. 269:13979-13987.
33. Borngraber, S., Kuban, R.J., Anton, M., and Kühn H. 1996. Phenylalanine 353 is a primary determinant for the positional specificity of mammalian 15-lipoxygenases. J Mol. Biol. 264:1145-1153.
34. Ylä-Herttuala, S., et al. 1990. Colocalization of 15-lipoxygenase mRNA and protein with epitopes of oxidized low density lipoprotein in macrophage-rich areas of atherosclerotic lesions. Proc. Natl. Acad. Sci. USA. 87:6959-6963.
35. Ylä-Herttuala, S., et al. 1991. Gene expression in macrophage-rich human atherosclerotic lesions. 15-lipoxygenase and acetyl low density lipoprotein receptor messenger RNA colocalize with oxidation specific lipid-protein adducts. J. Clin. Invest. 87:1146-1152.
36. Hiltunen, T., Luoma, J., Nikkari, T., and Ylä-Herttuala, S. 1995. Induction of 15-lipoxygenase mRNA and protein in early atherosclerotic lesions. Circulation. 92:3297-3303.
37. Kühn, H., Belkner, J., Zaiss, S., Fährenklempner, T., and Wohlfeil, S. 1994. Involvement of 15-lipoxygenase in early stages of atherogenesis. J. Exp. Med. 179:1903-1911.
38. Folcik, V.A., Nivar-Aristy, R.A., Krajewski, L.P., and Cathcart, M.K. 1995. Lipoxygenase contributes to the oxidation of lipids in human atherosclerotic plaques. J. Clin. Invest. 96:504-510.
39. Kühn, H., Heydeck, D., Hugou, I., and Gniwotta, C. 1997. In vivo action of 15-lipoxygenase in early stages of human atherogenesis. J. Clin. Invest. 99:888-893.
40. Kühn, H., and Chan, L. 1997. The role of 15-lipoxygenase in atherogenesis: pro- and antiatherogenic actions. Curr. Opin. Lipidol. 8:111-117.
41. Feinmark, S.J., and Cornicelli, J.A. 1997. Is there a role for 15-lipoxygenase in atherogenesis? Biochem. Pharmacol. 54:953-959.
42. Sendobry, S.M., et al. 1997. Attenuation of diet-induced atherosclerosis in rabbits with a highly selective 15-lipoxygenase inhibitor lacking significant antioxidant properties. Br. J. Pharmacol. 120:1199-1206.
43. Bocan, T., et al. 1998. A specific 15-lipoxygenase inhibitor limits the progression and monocyte-macrophage enrichment of hypercholesterolemia-induced atherosclerosis in the rabbit. Atherosclerosis. 136:203-216.
44. Shen, J., et al. 1997. Macrophage-mediated 15-lipoxygenase expression protects against atherosclerosis development. J. Clin. Invest. 98:2201-2208.
45. Sun, D., and Funk, C.D. 1996. Disruption of 12/15-lipoxygenase expression in peritoneal macrophages. Enhanced utilization of the 5-lipoxygenase pathway and diminished oxidation of low density lipoprotein. J. Biol. Chem. 271:24055-24062.
46. Plump, A.S., et al. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:343-353.
47. Linton, M.F., Atkinson, J.B., and Fazio, S. 1995. Prevention of atherosclerosis in apolipoprotein E-deficient mice by bone marrow transplantation. Science. 267:1034-1037.
48. Leenen, P.J., de Bruijn, M.F., Voerman, J.S., Campbell, P.A., and van Ewijk, W. 1994. Markers of mouse macrophage development detected by monoclonal antibodies. J. Immunol. Methods. 174:5-19.
49. Zhang, H.S., Reddick, R.L., Piedrahita, J.A., and Maeda, N. 1992. Spontaneous hypercholesterolemia and arterial lesions in mice lacking apolipoprotein E. Science. 258:468-471.
50. Palinski, W., Tangirala, R.K., Miller, E., Young, S.G., and Witztum, J.L. 1995. Increased autoantibody titers against epitopes of oxidized LDL in LDL receptor-deficient mice with increased atherosclerosis. Arterioscler. Thromb. Vasc. Biol. 15:1569-1576.
51. Nakashima, Y., Plump, A.S., Raines, E.W., Breslow, J.L., and Ross, R. 1994. ApoE-deficient mice develop lesions of all phases of atherosclerosis throughout the arterial tree. Arterioscler. Thromb. Vasc. Biol. 14:133-140.
52. Conrad, D.J., Kühn, H., Mulkins, M., Highland, E., and Sigal, E. 1992. Specific inflammatory cytokines regulate the expression of human monocyte 15-lipoxygenase Proc. Natl. Acad. Sci. USA. 89:217-221.
53. Nassar, G.M., Morrow, J.D., Roberts, L.J., Lakkis, F.G., and Badr, K.F. 1994. Induction of 15-lipoxygenase by interleukin-13 in human blood monocytes. J. Biol. Chem. 269:27631-27634.
54. Kroschwald, P., et al. 1989. Occurrence of the erythroid cell specific arachidonate 15-lipoxygenase in human reticulocytes. Biochem. Biophys. Res. Commun. 160:954-960.
55. Rokach, J., et al. 1997. Nomenclature of isoprostanes: a proposal. Prostaglandins. 54:853-873.
56. Ylä-Herttuala, S., Luoma, J., Vilta, H., Hiltunen, T., and Nikkari, T. 1995. Transfer of 15-lipoxygenase gene into rabbit iliac arteries results in the appearance of oxidation-specific lipid-protein adducts characteristic of oxidized low density lipoprotein. J. Clin. Invest. 95:2692-2698.
57. Benz, D.J., et al. 1995. Enhanced levels of lipoperoxides in low density lipoprotein incubated with murine fibroblast expressing high levels of human 15-lipoxygenase. J. Biol. Chem. 270:5191-5197.
58. Ezaki, M., Witztum, J.L., and Steinberg, D. 1995. Lipoperoxides in LDL incubated with fibroblasts that overexpress 15-lipoxygenase. J. Lipid. Res. 36:1996-2004.
59. Sigari, F., Lee, C., Witztum, J.L., and Reaven, P.D. 1997. Fibroblasts that overexpress 15-lipoxygenase generate bioactive and minimally modified LDL. Arterioscler. Thromb. Vasc. Biol. 17:3639-3645.
60. Tontonoz, P., Nagy, L., Alvarez, J.G., Thomazy, V.A., and Evans, R.M. 1998. PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell. 93:241-252.
61. Nozaki, S.,et al. 1995. Reduced uptake of oxidized low density lipoproteins in monocyte-derived macrophages from CD36-deficient subjects. J. Clin. Invest. 96:1859-1865.